Johnson & Johnson vs NOVO NORDISK A/S, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where JNJ and NVO diverge most: on ev/ebitda, JNJ reads 123.3 and NVO reads 8.9; on revenue growth, JNJ reads +8.1% and NVO reads +22.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | JNJ | NVO |
|---|---|---|
| Price | $261.50 | $38.62 |
| Market cap | $638.1B | $171.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Growth |
| P/E | 30.4 | 11.4 |
| P/B | 7.51 | 6.01 |
| P/S | 6.52 | 3.78 |
| EV/EBITDA | 123.3 | 8.9 |
| Revenue growth | +8.1% | +22.1% |
| Gross margin | 68.2% | 81.0% |
| Operating margin | — | 41.3% |
| Net margin | 21.5% | 33.1% |
| Return on equity | 24.8% | 52.8% |
| Return on assets | 10.5% | 18.9% |
| Return on invested capital | — | 30.8% |
| FCF yield | 3.5% | 5.0% |
| Dividend yield | 2.0% | — |
| Debt / equity | 0.58 | 0.67 |
| Current ratio | 1.09 | 0.80 |
| Altman Z (solvency) | 5.01 | 3.76 |
| Piotroski F (quality) | 8 / 9 | 3 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.